José Antonio García Salcedo-rekin lankidetzan egindako argitalpenak (9)

2015

  1. Relationship between proinflammatory and antioxidant proteins with the severity of cardiovascular disease in type 2 diabetes mellitus

    International Journal of Molecular Sciences, Vol. 16, Núm. 5, pp. 9469-9483

  2. Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis

    PLoS Pathogens, Vol. 11, Núm. 6

2014

  1. Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids

    Osteoporosis International, Vol. 25, Núm. 2, pp. 645-651

2013

  1. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels

    Diabetes Care, Vol. 36, Núm. 6, pp. 1667-1674

  2. Serum osteoprotegerin: Bone or cardiovascular marker in Type 2 diabetes males?

    Journal of Endocrinological Investigation, Vol. 36, Núm. 1, pp. 16-20

2012

  1. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus

    Journal of Clinical Endocrinology and Metabolism, Vol. 97, Núm. 1, pp. 234-241

  2. Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes

    Diabetes and Metabolism, Vol. 38, Núm. 1, pp. 76-81

2011

  1. Pentosidina: Un nuevo biomarcador de las complicaciones en la diabetes mellitus

    Medicina Clinica, Vol. 136, Núm. 7, pp. 298-302

2010

  1. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor κb in women with postmenopausal osteoporosis

    Menopause, Vol. 17, Núm. 1, pp. 140-144